PRC-063 oral capsules

DRUG2 trials

Sponsors

Purdue Pharma, Canada

Conditions

ADHD

Phase 3

PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD

CompletedNCT03172481

Purdue Pharma, CanadaADHD

Start: 2017-05-01End: 2017-12-19Updated: 2019-11-05

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

CompletedNCT03618030

Purdue Pharma, CanadaADHD

Start: 2018-08-21End: 2019-07-05Updated: 2021-07-26

Related Papers

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adult Laboratory Classroom Study of the Efficacy and Safety of PRC-063 (Extended-Release Methylphenidate) for the Treatment of ADHD

Journal of Attention Disorders2021-06-308 citations

Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension.

2021-05-316 citations

Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6–12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study

Journal of Child and Adolescent Psychopharmacology2020-10-2216 citations